Cancer Research Meeting Calendar  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wodarz, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wodarz, D.
[Cancer Research 63, 8554, December 1, 2003]
© 2003 American Association for Cancer Research


Letters to the Editor

Correspondence re: L. M. Wein et al., Validation and Analysis of a Mathematical Model of a Replication-Competent Oncolytic Virus for Cancer Treatment: Implications for Virus Design and Delivery. Cancer Res., 63: 1317–1324, 2003.

Dominik Wodarz

Fred Hutchinson Cancer Research Center, Seattle, WA

Letter

The use of replication-competent viruses for the treatment of cancers is a rapidly growing area of research and offers an important strategy to specifically target tumor cells (1, 2, 3, 4, 5) . A number of viruses, which can specifically infect cancer cells, have been explored in this context and have shown promising results. Identification of the optimal characteristics of such viruses is, however, a challenging task. Mathematical models and computer simulations can offer important insights and influence the design of such treatment regimes. A recent article by Wein et al. (6) provides a mathematical analysis of this question, assuming the spread of a virus through a tumor in three-dimensional space. Their model suggests that tumor reduction is promoted by efficient distribution and spread of the virus through the tumor, by elimination of immune responses, and by rapid virus-induced killing of infected tumor cells.

Recently, I have studied the same question with simpler mathematical models that did not take spatial considerations into account (7 , 8) . Although many of the basic results of this study agree with the findings of Wein et al. (6) , there is an important difference regarding the rate of virus-induced tumor cell killing. My models (7) suggest that maximizing the death rate of infected tumor cells can be detrimental to success because a high death rate of infected cells can impair the ability of the virus to spread through the tumor. Depending on the particular assumptions about the dynamics of infected cells (7 , 8) , the model predicted an optimal rate of virus-induced cell killing. Similarly, for immune effector mechanisms that kill infected cells, the model suggested an optimal strength of these responses.

Wein et al. (6) point out that the higher complexity of their model such as the explicit treatment of space is an important difference between the two approaches. A closer look at their model suggests, however, that the difference in outcome is not the result of the higher complexity but the result of a difference in assumption of the basic viral dynamics underlying the models. Wein et al. (6) assume that the rate of virus release from infected cells is linearly proportional to the death rate of the cells and given by {delta}N, where N denotes the number of virus particles released and {delta} denotes the death rate of infected cells. That is, the faster the death rate of infected cells (higher value of {delta}), the larger the rate of virus production. This appears to be an unrealistic assumption. It means that infected cells produce a certain fixed number of viruses during their life, independent of their life span (the basic reproductive ratio of the virus is independent of the life span of infected cells). Furthermore, this number of viruses can be present in the cells and ready for release immediately upon infection. Thus, according to Wein et al. (6) , an infinitely short life span of the infected cells, brought about by the virus, is most beneficial for therapy. My model, on the other hand, assumes that virus accumulates inside the infected cells over time. Thus, killing the cell too early (higher value of {delta}) can result in the release of fewer virus particles and in a suboptimal outcome of treatment. My model assumes that the virus accumulates linearly during the life span of the infected cell before it is killed. This might not be realistic either. Once a time threshold has been crossed and the cell has accumulated a number of virus particles, virus production might slow down. In this case, a higher rate of cell killing might benefit treatment, as suggested by Wein et al. (6) . This discussion is similar to arguments in epidemiology regarding the relationship between pathogen virulence (host killing) and the replication rate of the pathogen. Detailed epidemiological studies suggest that this relationship is complex and that an optimal rate of killing might maximize virus spread (9 , 10) . The same is likely to apply to oncolytic viruses. The assumption that the basic reproductive ratio of the virus does not depend on the life span of infected cells is unlikely to be realistic.

In summary, these arguments show that simply maximizing the rate of virus-induced cell killing is not a correct strategy for treatment and that the relationship between tumor reduction and virus-induced cell killing can be more complicated and merits additional experimental investigation. Similarly, abolishing lytic immune responses might also be detrimental for therapy because these responses modulate the death rate of infected cells and can push it toward an optimum value in defined parameter regions. The notion that a reduced or an intermediate death rate of virus-infected cells can lead to most efficient tissue destruction has been shown experimentally in a different context: an intermediate strength of the CD8 T-cell response can maximize T-cell-induced pathology in murine lymphocytic choriomeningitis virus infection (11) .

FOOTNOTES

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 4/30/03. Accepted 5/30/03.

REFERENCES

  1. Bischoff J. R., Kirn D. H., Williams A., Heise C., Horn S., Muna M., Ng L., Nye J. A., Sampson-Johannes A., Fattaey A., McCormick F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [see comments]. Science (Wash. DC), 274: 373-376, 1996.[Abstract/Free Full Text]
  2. Kirn D. H., McCormick F. Replicating viruses as selective cancer therapeutics. Mol. Med. Today, 2: 519-527, 1996.[Medline]
  3. Heise C. C., Williams A., Olesch J., Kirn D. H. Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther., 6: 499-504, 1999.[Medline]
  4. Harrison D., Sauthoff H., Heitner S., Jagirdar J., Rom W. N., Hay J. G. Wild-type adenovirus decreases tumor xenograft growth, but despite viral persistence complete tumor responses are rarely achieved: deletion of the viral E1b-19-kD gene increases the viral oncolytic effect. Hum. Gene Ther., 12: 1323-1332, 2001.[Medline]
  5. Taneja S., MacGregor J., Markus S., Ha S., Mohr I. Enhanced antitumor efficacy of a herpes simplex virus mutant isolated by genetic selection in cancer cells. Proc. Natl. Acad. Sci. USA, 98: 8804-8808, 2001.[Abstract/Free Full Text]
  6. Wein L. M., Wu J. T., Kirn D. H. Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. Cancer Res., 63: 1317-1324, 2003.[Abstract/Free Full Text]
  7. Wodarz D. Viruses as antitumor weapons: defining conditions for tumor remission. Cancer Res., 61: 3501-3507, 2001.[Abstract/Free Full Text]
  8. Wodarz D. Gene therapy for killing p53-negative cancer cells: use of replicating versus nonreplicating agents. Hum. Gene Ther., 14: 153-159, 2003.[Medline]
  9. Lipsitch M., Moxon E. R. Virulence and transmissibility of pathogens: what is the relationship?. Trends Microbiol., 5: 31-37, 1997.[Medline]
  10. Gandon S., Mackinnon M. J., Nee S., Read A. F. Imperfect vaccines and the evolution of pathogen virulence. Nature (Lond.), 414: 751-756, 2001.[Medline]
  11. Christensen J. P., Bartholdy C., Wodarz D., Thomsen A. R. Depletion of CD4+ T cells precipitates immunopathology in immunodeficient mice infected with a noncytocidal virus. J. Immunol., 166: 3384-3391, 2001.[Abstract/Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wodarz, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wodarz, D.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online